{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055606","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.316291+00:00","generated_at":"2026-06-02T10:27:22.480593+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Revolution Medicines Q1 net loss $116M; cash $1.70B; plans pivotal RMC-6236 trials in H2 2024","bullets":["Net loss of $116.0M for Q1 2024, compared to $68.1M in Q1 2023.","Revenue $0 (ended Sanofi collaboration); R&D expenses $118.0M (up from $68.9M).","Cash $1.70B as of March 31, 2024; projected cash runway into 2027.","Plans to initiate two pivotal monotherapy trials of RMC-6236 in 2L PDAC and 2L NSCLC in H2 2024.","Reiterates FY2024 GAAP net loss guidance between $480M and $520M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055606","json":"https://secwatch.observer/filing/0000950170-24-055606.json","markdown":"https://secwatch.observer/filing/0000950170-24-055606.md","text":"https://secwatch.observer/filing/0000950170-24-055606.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/0000950170-24-055606-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/rvmd-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T10:27:22.480593+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0905bef209af73bdd41889ddf8f125f5f2e69924","claim":"Revolution Medicines, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 8, 2024, Revolution Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024055606/0000950170-24-055606-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}